Table 2

Characteristics of initial immune-related adverse events (irAEs)

	Discontinuation (n=44)		Retreatment (n=36)
	N/median	%/range	N/median	%/range	P value
Type of irAE
Elevated AST/ALT	11	25.0%	5	13.9%
Colitis	10	22.7%	6	16.7%
Pneumonitis	5	11.4%	3	8.3%
Skin	3	6.8%	5	13.9%
Elevated lipase	2	4.6%	5	13.9%
Adrenal insufficiency	2	4.6%	2	5.6%
Hypophysitis	2	4.6%	3	8.3%
Nephritis	2	4.6%	1	2.8%
Arthritis	1	2.3%	3	8.3%
Encephalitis	1	2.3%	0	0.0%
Hypothyroidism	1	2.3%	1	2.8%
Myocarditis	1	2.3%	0	0.0%
Other	1	2.3%	1	2.8%
Peripheral neuropathy	1	2.3%	0	0.0%
Polymyalgia rheumatica	1	2.3%	0	0.0%
Type 1 diabetes	0	0.0%	1	2.8%
Grade of irAE					0.37
G1/2	18	40.9%	19	52.8%
G3/4	26	59.1%	17	47.2%
Hospitalization*					0.007
No	15	34.1%	24	66.7%
Yes	29	65.9%	12	33.3%
Any steroid use (local or systemic)*					0.007
No	7	15.9%	16	44.4%
Yes	37	84.1%	20	55.6%
Systemic steroid use					0.28
No	1	2.7%	2	10.0%
Yes	36	97.3%	18	90.0%
Systemic steroid use ≥40 mg*					0.01
No	6	16.2%	10	50.0%
Yes	31	83.8%	10	50.0%
Duration of steroid course >4 weeks					0.64
No	4	10.8%	1	5.0%
Yes	33	89.2%	19	95.0%
Additional line of immunosuppression					0.37
No	40	90.9%	35	97.2%
Yes	4	9.1%	1	2.8%
Time to irAE onset, mos	2.7	0.4–74.7	2.8	0.3–46.1	0.59
Therapy interruption before retreatment, mos	NA	NA	0.9	0.2–31.6